Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy

Diabetes

Volumn 48, Issue 5, 1999, Pages 1108-1112

  Fernández Real, José Manuel ^a   Molina, Ana ^b   Broch, Montserrat ^c   Ricart, Wifredo ^a   Gutiérrez, Cristina ^c   Casamitjana, Roser ^d   Vendrell, Joan ^c   Soler, Joan ^b   Gómez Sáez, José Manuel ^b  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATINE KINASE; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MYOTONIC DYSTROPHY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; BODY CONSTITUTION; BODY MASS INDEX; CHOLESTEROL, LDL; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERLIPIDEMIAS; INSULIN; INSULIN RESISTANCE; LINEAR MODELS; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; RECEPTORS, TUMOR NECROSIS FACTOR; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344731419     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.5.1108     Document Type: Article

References (42)

1. Harper PS: Myotonic disorders. In Myology. Engel AG, Banker BQ, Eds. New York, McGraw-Hill, 1986, p. 1267-1311
2. Aslanidis C, Jansen G, Ameniya C, Shutler G, Mahadevan M, Tsilfidis C, Chen C, Alleman J, Wormskamp NGM, Vooijs M, Buxton J, Johnson K, Smeels HJM, Lennon GG, Carrano AV, Korneluk RG, Wieringa B, De Jong PJ: Cloning of the essential myotonic dystrophy region and mapping of the putative defect. Nature 353:548-551, 1992
3. Tevaarwerk GJM, Strickland KP, Lin CH, Hudson AJ: Studies on insulin resistance and insulin receptor binding in myotonia dystrophica. J Clin Endocrinol Metab 49:216-222, 1979
4. Moxley RT III, Griggs RC, Goldblat D: Muscle insulin resistance in myotonic dystrophy: effect of supraphysiologic insulinization. Neurology 30:1977-1083, 1980
5. Beutler B, Cerami A: The biology of cachectin/TNF-α primary mediator of the host response. Annu Rev Immunol 7:625-655, 1989
6. Grunfeld C, Feingold KR: The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 3:143-158, 1991
7. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111-2119, 1995
8. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95:2409-2415, 1995
9. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA: The expression of TNF-α by human muscle: relationship to insulin resistance. J Clin Invest 97:1111-1116, 1996
10. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science 271:665-668, 1996
11. Tartaglia LA, Goeddel DV: Two TNF receptors. Immunol Today 13:151-153, 1992
12. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76:959-962, 1994
13. Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717-1725, 1996
14. Seckinger P, Isaaz S, Dayer JM: Purification and biologic characterization of a specific tumor necrosis factor-α inhibitor. J Biol Chem 264:11966-11973, 1989
15. Nophar Y, Kemper O, Brakebusch C, Engelmann H, Zwang R, Aderka D, Holtmann H, Wallach D: Soluble forms of tumor necrosis factors (TNF-Rs): the cDNA for the type ITNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 9:3269-3278, 1990
16. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323-329, 1992
17. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM: Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 46:451-455, 1997
18. Fernández-Real JM, Broch M, Ricart W, Casamitjana R, Gutierrez C, Vendrell J, Richart C: Plasma sTNFR2 levels and insulin resistance. Diabetes 1998; 47:1757-1762
19. Lundberg I, Brengman JM, Engel AG: Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 63:9-16, 1995
20. Tews DS, Goebel HH: Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55:342-347, 1996
21. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
22. Cederholm J, Wibell L: Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 10:167-175, 1990
23. Bergman RN, Prager R, Volund A, Olefsky JM: Equivalence of the insulin sensitivity index in man derived by the minimal model method and euglycaemic glucose clamp. J Clin Invest 79:790-800, 1987
24. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW: Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 29:1075-1080, 1983
25. Kostner GM, Molinari E, Pichler P: Evaluation of a new HDL2/HDL3 quantitation method based on precipitation with polyethylene glycol Clin Chim Acta 148:139-147, 1985
26. Wahlefeld AW: Methoden der Enzymatischen Analyse. Bergmeyer HU, Ed. Vol II, 3rd ed. Weinheim, Germany, Verlag Chemie, 1974, p. 187-188
27. Winzen R, Wallach D, Kemper O, Resch K, Holtmann H: Selective upregulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. J Immunol 150:4346-4353, 1993
28. Gómez-Sáez JM, Fernández-Real JM, Fernández-Castañer M, Navarro Moreno MA, Martínez-Matos JA, Soler Ramón J: Study on growth hormone and insulin secretion in myotonic dystrophy. Clin Invest 72:508-511, 1994
29. Aderka D, Engelmann H, Hornik V, Skomick Y, Levo Y, Wallach D, Kustai G: Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 51:5602-5607, 1991
30. Mably E, Strickland KP, Tevaarwerk GJ, Hudson AJ: Glucose transport and oxidation in adipose tissue of patients with myotonic dystrophy. J Neuro Sci 52:11-23, 1981
31. Roses AD, Appel SH: Muscle membrane protein kinase in myotonic muscular dystrophy. Nature 250:245-246, 1974
32. Hohenberger P, Haier J, Schlag PM: Rhabdomyolysis and renal function impairment after isolated limb perfusion: comparison between the effects of perfusion with rhTNF-α and a "triple-drug" regimen. Eur J Cancer 33:596-601, 1997
33. Grunfeld C, Feingold KR: Role of cytokines in inducing hyperlipidemia. Diabetes 41 (Suppl. 2): 97-101, 1992
34. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR: Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74:1045-1052, 1992
35. Levy E, Gurbindo C, Lacaille F, Paradis K, Thibault L, Seidman E: Circulating tumor necrosis factor-α levels and lipid abnormalities in patients with cystic fibrosis. Pediatr Res 34:162-166, 1993
36. Poffenbarger PL, Bozefsky T, Soeldner JS: The direct relationship of proinsulin-insulin hypersecretion to basal serum levels of cholesterol and triglyceride in myotonic dystrophy. J Lab Clin Med 87:384-396, 1976
37. Memon RA, Grunfeld C, Moser AH, Feingold KR: Tumor necrosis factor mediates the effect of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 132:2246-2253, 1993
38. Lawler JF Jr, Yin M, Diehl AM, Roberts E, Chatterjee S: Tumor necrosis factor-α stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem 273:5053-5059, 1998
39. Lopes-Virella M, Virella G: Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes 45 (Suppl. 3):S40-S44, 1996
40. Brito BE, Romano EL, Grunfeld C: Increase lipopolysaccharide-induced tumour necrosis factor levels and death in hypercholesterolaemic rabbits. Clin Exp Immunol 101:357-361, 1996
41. Henninger DD, Gerritsen ME, Granger DN: Low-density lipoprotein receptor knockout mice exhibit exaggerated microvascular responses to inflammatory stimuli. Circ Res 81:274-281, 1997
42. Fleet JC, Clinton SK, Salomon RN, Loppnow H, Libby P: Atherogenic diets enhance endotoxin-stimulated interleukin-1 and tumor necrosis factor gene expression in rabbit aortae. JNutr 122:294-305, 1992